Setmelanotide
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
Rhythm · Phase 3 · Completed · Enrollment 15
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- Setmelanotide: week 52 -25.83%
One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.